Hahn was approved for FDA commissioner in an 18-5 vote, after he was put forward for the job by President Donald Trump.
The Senate Committee on Health, Education, Labor and Pensions voted in favour of advancing Hahn’s nomination to the full Senate.
If he is confirmed again, Hahn will go on to head the FDA and become a pivotal figure on a number of key issues the agency is currently facing.
One of these issues is the prevalence of vaping among adolescents – during his confirmation hearing last month, Hahn was questioned about how he would handle the epidemic, and whether he would potentially ban flavoured vape products.
He avoided this line of questioning, instead responding that he could not prejudge the policy and ‘would let science guide his work’.
Interim acting FDA commissioner Ned Sharpless returned to his role as the director of the National Cancer Institute, after completing his tenure at the federal agency on 1 November…